Results 251 to 260 of about 1,921,670 (307)

Cellular immunotherapy for acute myeloid leukemia: from bench to bedside. [PDF]

Immunother Adv
Wang Y, Wu J, Huang X, Xiao Y.
europepmc   +1 more source

Metallothionein Isoforms in Acute Myeloid Leukemia: Roles in Survival, Differentiation, and Stress Adaptation. [PDF]

Hematol Rep
Takahashi S.
europepmc   +1 more source

Extracellular Vesicles in Acute Myeloid Leukemia: Opportunities and Obstacles for Therapeutic Advancement. [PDF]

J Biochem Mol Toxicol
Hu R, Ataullev Z, Lou L.
europepmc   +1 more source

Presenting a multi-marker response-adapted framework for venetoclax duration in acute myeloid leukemia. [PDF]

Ann Hematol
Adnan N.
europepmc   +1 more source

Race and Ethnicity and Overall Survival in Pediatric Acute Myeloid Leukemia.

JAMA Netw Open
Zheng DJ, Khuong L, Aftandilian C, Bona K, Caywood EH, Elgarten CW, Fisher BT, Gathers CL, Ghosh T, Gramatges MM, Hettinger G, Henry MR, Huang YV, Li Y, Maloney K, Mian A, Miller TP, Modi A, Mody R, Myers RM, Newman H, Ortiz J, Seif AE, Smith C, Stokke J, Winick N, Wilkes JJ, Wong V, Aplenc R, Getz KD.   +29 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Venetoclax in acute myeloid leukemia

Expert Opinion on Investigational Drugs, 2023
Background: Substantial progress in the therapeutic arsenal used to treat acute myeloid leukemia became possible in the last decade, as a result of advances in gene editing and descriptive and functional genomics. Objective: The aim of this study is to analyze the efficacy and safety of venetoclax in the treatment of acute myeloid leukemia ...
Bruzzese, Antonella, Martino, Enrica Antonia, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, Gentile, Massimo   +8 more
openaire   +4 more sources

Acute Myeloid Leukemia

Journal of the National Comprehensive Cancer Network, 2008
Approximately 13,290 people will be diagnosed with acute myeloid leukemia (AML) in 2008, and 8820 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Clinical trials have led to significant treatment improvements in some areas, primarily acute promyelocytic leukemia.
Margaret R, O'Donnell, Frederick R, Appelbaum, Steven E, Coutre, Lloyd E, Damon, Harry P, Erba, James, Foran, Jeffrey, Lancet, Lori J, Maness, Guido, Marcucci, Peter G, Maslak, Michael, Millenson, Joseph O, Moore, Farhad, Ravandi, Friedrich, Schuening, Paul, Shami, B Douglas, Smith, Richard M, Stone, Martin S, Tallman, Eunice, Wang, Frank L, White   +19 more
openaire   +5 more sources

SEPHguarding acute myeloid leukemia

Cell Stem Cell, 2022
Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.
Malini, Gupta, Britta, Will
openaire   +2 more sources